Any UK aesthetic practitioner who examines skin has a clinical duty to act on suspicious lesions. NICE guideline NG12 sets the threshold: an urgent two-week-wait referral for any feature consistent with melanoma, squamous cell carcinoma, or basal cell carcinoma. That duty applies to every registered clinician, regardless of whether their practice is cosmetic or therapeutic.
Why Skin Cancer Awareness Belongs in Aesthetic Practice
UK aesthetic practitioners occupy a particular clinical position. They examine skin in detail, at close range, during consultations and treatment sessions. The face, neck, décolletage, scalp, and hands are the most common treatment areas in any aesthetic clinic. They are also the body regions with the highest cumulative ultraviolet exposure over a patient's lifetime.
The UK records among the highest melanoma incidence rates in Europe. Cases have risen sharply over the past two decades. Skin cancer charity data consistently show that outcomes are closely tied to how early the lesion is identified and referred. A stage I melanoma has a ten-year survival rate above 95 percent. At stage IV, that figure falls to under 20 percent.
Aesthetic practitioners are not cancer screeners. That is not the point. The point is that practitioners who examine a patient's face and neck in good clinical lighting are sometimes the first person to look at a lesion carefully. A patient may not have noticed it. Their GP appointment may have covered something else. The aesthetic consultation, by contrast, often involves careful, well-lit, close-range examination of exactly the areas where skin cancers appear.
That clinical window creates a duty. The JCCP competency framework identifies patient welfare as a core practitioner obligation, not a bolt-on to technical skill. Recognising a lesion that warrants urgent review is part of exercising that obligation.
What the NICE Guidance Requires
NICE guideline NG12, Suspected cancer: recognition and referral, was last updated in April 2026. It is addressed to all registered clinicians who examine patients, not only GPs. It sets out referral criteria for skin cancers and the timeframes attached to each.
Under NG12, an urgent two-week-wait referral is indicated when examination identifies:
Melanoma features. Any pigmented lesion with more than one ABCDE warning sign, or any lesion that has changed, itches, or bleeds without trauma. New pigmented lesions in adults over 40 warrant particular attention.
Squamous cell carcinoma (SCC) features. A growing, crusted, ulcerated, or firm lesion on sun-exposed skin, particularly in older patients, those with a history of significant ultraviolet exposure, or anyone on long-term immunosuppression.
Basal cell carcinoma (BCC) features. A slowly growing, pearlescent, or rolled-edge lesion, often on the face. BCCs rarely metastasise, but they destroy local tissue and can track deeply if left untreated.
A non-urgent but prompt referral is appropriate for any lesion that is uncertain in diagnosis. The bar is low by design. Clinical uncertainty is sufficient justification. NG12 is explicit that the threshold for referral should be when a practitioner is not confident the lesion is benign, not only when they are confident it is malignant.
The British Association of Dermatologists' skin cancer service guidance, published in December 2024, reinforces this framework and emphasises the role of non-dermatologist clinicians in driving timely pathways. Every skin cancer that reaches a specialist has first been examined by someone else. The quality of that first encounter shapes what happens next.
The ABCDE Warning Signs in Detail
The ABCDE criteria are taught across clinical disciplines and endorsed by dermatology bodies internationally.
A — Asymmetry. One half of the lesion does not mirror the other. A benign naevus is typically symmetrical. Asymmetry in shape, pigment distribution, or structure is a warning.
B — Border. Irregular, ragged, notched, or poorly defined borders. Sharply demarcated and regular edges are generally reassuring.
C — Colour. Variation within a single lesion: brown, black, red, white, or blue tones present in the same lesion. Uniform colour, even if dark, is typically lower risk than colour variation.
D — Diameter. Lesions larger than 6mm raise suspicion. This is a rule of thumb, not a threshold. Smaller melanomas exist, and a 4mm lesion with other warning features warrants referral.
E — Evolution. Change over time is the single most clinically significant flag. Any lesion that has grown, changed shape, altered colour, or developed new symptoms in recent months should be treated as suspicious until a specialist confirms otherwise.
Beyond ABCDE, additional red flags include bleeding without trauma, persistent itching, ulceration, or a satellite lesion appearing near an existing naevus. Any lesion the patient mentions having changed recently is a referral candidate, not a monitor-and-review case.
The Referral Process in Clinical Practice
UK aesthetic practitioners registered with a professional body (NMC, GMC, GDC, or GPhC) have a clinical duty to act when they identify a suspicious lesion. The referral mechanism depends on practice setting.
Prescribing practitioners (nurse prescribers, doctors, dentists) can initiate a two-week-wait referral directly via the patient's GP or, in some commissioning areas, via a direct-access dermatology pathway. The referral should specify the clinical findings, anatomical location, and urgency.
Non-prescribing practitioners should escalate immediately to their clinical lead or supervising prescriber. A patient should not leave the appointment without being told clearly that the lesion needs medical review and how to access it. Telling a patient to see their GP is appropriate. Advising them there is no rush when the lesion meets NG12 criteria is not.
Non-clinical practitioners working in beauty or aesthetics settings without a registered healthcare qualification have a different legal position. They do not have a clinical referral route. Their obligation is to the patient's welfare: telling someone clearly and directly that what you have seen needs a GP appointment, today if possible, meets that obligation.
When referring, the clinical record should capture:
- Anatomical site and description of the lesion (size, shape, border, colour, surface characteristics)
- Any relevant patient history (previous skin cancers, immunosuppression, significant UV history)
- ABCDE features observed
- When the lesion was first noticed (by patient and by practitioner)
- What was communicated to the patient
- What referral action was taken and to whom
If a patient declines referral after clinical advice, document the advice given, their response, and the date. A note that records only "advised to see GP" is not sufficient if the lesion met urgent criteria.
What Aesthetic Practitioners Should Not Do
The practitioner's role here is recognition and referral, not diagnosis or management. Several boundaries matter.
Do not diagnose. Describing a lesion as benign, or reassuring a patient that it looks fine, without dermatology training and dermoscopy falls outside clinical scope. Document what was observed and refer.
Do not use dermoscopy without training. Dermoscopy in untrained hands does not improve lesion assessment. It requires formal training to reduce, rather than increase, the risk of missing a cancer. Owning a handheld device is not the same as being able to use it clinically.
Do not monitor without referral. Photographing a suspicious lesion and reviewing it at the next appointment is not a clinical monitoring strategy. If the lesion meets referral criteria today, refer today.
Do not delay referral to complete a treatment course. A treatment course can pause. An unmanaged melanoma will not.
The UK aesthetic regulation framework has always framed practitioner conduct as a patient protection matter first. What a practitioner does when they find something unexpected tells the patient whether the clinic they chose is genuinely clinically led.
Documentation and Clinical Governance
In any clinical encounter where a finding outside the practitioner's direct scope is identified, the record needs to show that the finding was noticed, assessed to the extent of the practitioner's competence, communicated to the patient, and acted on.
This is not additional bureaucracy. It is standard clinical governance. For registered practitioners, it is also professional protection: the record is evidence that due care was taken if a complaint or regulatory investigation arises.
Most aesthetic software allows free-text clinical notes alongside treatment records. A brief clinical note, two or three sentences describing the lesion and the action taken, takes under two minutes and provides a permanent record.
For practitioners who want a structured grounding in clinical governance, documentation duties, and the professional standards framework that underlies safe practice, the RAG Pathway is built around exactly that evidence base. The same principles that govern compliance in regulation shape clinical safety in practice. Bernadette's clinical background, managing skin conditions across many years in primary and aesthetic care, informs how the programme approaches the practitioner's professional obligations.
FAQ
Do aesthetic practitioners have a duty to act on suspicious skin lesions they find during a cosmetic appointment?
Yes. Any registered clinician who examines a patient has a duty of care that extends beyond the cosmetic purpose of the appointment. NICE NG12 applies to all registered clinicians, not only GPs. Identifying a suspicious lesion and taking no action is a patient safety failure, regardless of the clinical setting.
Can a nurse aesthetic practitioner make an urgent referral directly?
A nurse prescriber registered with the NMC can initiate an urgent two-week-wait referral either via the patient's GP or via local urgent pathway arrangements, depending on commissioning. Non-prescribing nurses should escalate to their clinical lead immediately. The patient's outcome must not be delayed by the prescribing status of the practitioner who found the lesion.
What if the patient says they will see their GP themselves?
Document the clinical observation, the advice given, and the patient's response. If the lesion carried high suspicion, the record should reflect the urgency communicated. Following up briefly at a later point to confirm the patient attended is good clinical practice, not overstepping. A lesion that met NG12 referral criteria is not a monitoring case.
What is the two-week-wait pathway?
The urgent referral pathway under NICE NG12 ensures that patients with suspected cancer are seen by a specialist within two weeks of referral. The purpose is to rule cancer in or out at specialist level, not to diagnose in the referring setting. The quality of the referral letter, including what the referring clinician observed, directly influences how the specialist triages the appointment.
Does this apply only to medically qualified aesthetic practitioners?
Registered healthcare professionals (nurses, doctors, dentists, pharmacists, physiotherapists) have a formal professional duty to act on clinical findings regardless of their practice setting. Non-clinical practitioners in aesthetics or beauty have a moral duty to direct patients to appropriate care. The referral mechanism differs; the obligation to tell a patient that a lesion needs medical review does not.